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Abstract
 
Tolerance is the usual outcome of inhalation of harmless antigen, yet T helper (Th) type 2 cell
sensitization to inhaled allergens induced by dendritic cells (DCs) is common in atopic asthma.
Here, we show that both myeloid (m) and plasmacytoid (p) DCs take up inhaled antigen in the
lung and present it in an immunogenic or tolerogenic form to draining node T cells. Strikingly,
depletion of pDCs during inhalation of normally inert antigen led to immunoglobulin E sensiti-
zation, airway eosinophilia, goblet cell hyperplasia, and Th2 cell cytokine production, cardinal
features of asthma. Furthermore, adoptive transfer of pDCs before sensitization prevented disease
in a mouse asthma model. On a functional level, pDCs did not induce T cell division but sup-
pressed the generation of effector T cells induced by mDCs. These studies show that pDCs
provide intrinsic protection against inflammatory responses to harmless antigen. Therapies ex-
ploiting pDC function might be clinically effective in preventing the development of asthma.
Key words: asthma • plasmacytoid dendritic cells • tolerance • mucosal immunity • 
regulatory T cell
 
Introduction
 
Asthma is an increasingly common disease that remains
poorly understood and difficult to manage. Its incidence has
doubled in westernized countries in the last two decades
and worldwide costs are estimated to exceed those from
tuberculosis and HIV/AIDS combined (1), necessitating a
way to prevent this disorder. Asthma is a Th2 lymphocyte–
mediated inflammatory airway disease characterized by airway
eosinophilia, increased mucus production by goblet cells,
and structural remodeling of the airway wall. This leads to
variable airway obstruction and to bronchial hyperrespon-
siveness to nonspecific stimuli. In allergic asthma, the presence
of high levels of allergen-specific IgE are a reflection of an
aberrant Th2 cell immune response to common inhaled
environmental allergens such as house dust mite or pollen
allergen (2). This process of Th2 cell sensitization to inhaled
allergens occurs at a very young age and is influenced by
environmental factors such as childhood infections and
environmental exposure to microbial compounds (3).
It is currently unknown how exposure to harmless inhaled
antigen such as allergen leads to prolonged Th2 cell sensitiza-
tion in individuals with allergy, as respiratory exposure to
harmless antigen is a tolerogenic event (4). Recent evidence
shows that airway DCs are at the focal control point deter-
mining the induction of pulmonary immunity or tolerance
(5–8). Airway DCs form a dense network in the lung ideally
placed to sample antigens and migrate to draining LNs to
stimulate naive T cells (9–12). Airway DCs play a central
role not only in initiating specific Th2 cell immune responses
leading to experimental asthma (13, 14), but they also restimu-
late effector cells during ongoing airway inflammation (8,
15–17). Less is known about the tolerogenic capacity of air-
way DCs. The immune response leading to inhalation tol-
erance is accompanied by a considerable degree of primary
T cell division in draining cervical and mediastinal LNs
(MLNs) and therefore it is likely that it also involves antigen
presentation by professional APCs (4, 18–21). In support of
this theory, DCs obtained from lung draining LNs of toler-
ized mice were able to induce T cell unresponsiveness ex
vivo and transfer tolerance to naive mice, in a process that
required active T cell costimulation through either CD86 or
ICOS-L (3, 5, 21). Despite the occurrence of inhalational
tolerance, some authors have witnessed sensitization to in-
haled inert antigen, particularly when signals activating the
innate immune system were coadministered (14, 22).
As inhalation of harmless antigen induces sensitization or
tolerance in a process controlled by lung DCs, we hypoth-
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esized that a more detailed study on the functional out-
come of antigen presentation by subsets of DCs in the lung
might provide insight into the decision governing tolerance
or immunity. We found that particular subsets of DCs were
able to take up and transport antigen in the lung. Whereas
myeloid DCs (mDCs) were important for generating T cell
division and priming, plasmacytoid DCs (pDCs) suppressed
T cell effector generation. Strikingly, in the absence of
pDCs, exposure to harmless antigen led to Th2 cell sensiti-
zation and to features of asthma.
 
Materials and Methods
 
Mice.
 
6–8-wk-old BALB/c mice were purchased from Har-
lan. OVA-TCR transgenic mice (DO11.10) on a BALB/c back-
ground were bred at the Erasmus Medical Center. All experi-
ments were performed according to institutional guidelines of the
animal ethics committee at Erasmus Medical Center.
 
Isolation of Bronchoalveolar, Lung, and LN Cells.
 
After anesthe-
sia with 2.5% avertin, mice were bled and bronchoalveolar lavage
(BAL) was performed using 3 
 
  
 
1 ml warm PBS containing 0.1
mM EDTA through a canula placed in the trachea (10). To ob-
tain single lung cell suspensions, lungs were perfused with 20 ml
PBS through the right ventricle, minced using iridectomy scis-
sors, and digested with collagenase III and DNase I, as described
previously (11). For obtaining single cell suspensions from LNs,
MLNs were excised, minced, and digested as described above.
After blocking the reaction with excess EDTA, cells (
 
 
 
95% via-
bility) were washed and stained for flow cytometry.
 
Flow Cytometry and Sorting.
 
All staining reactions were per-
formed at 4
 
 
 
C. First, cells were incubated with 2.4G2 Fc receptor
Ab to reduce nonspecific binding. Dead cells and debris were ex-
cluded using propidium iodide. To detect DCs, single cells were
stained with APC-labeled anti-CD11c (HL3) and FITC-labeled
anti–Gr-1 (RB6-8C5) Abs. The phenotype of CD11c
 
int 
 
Gr-1
 
 
 
(pDCs) and CD11c
 
hi 
 
Gr-1
 
  
 
(mDCs) cells was determined by us-
ing PE-labeled anti-B220 (RA3-6B2), CD8
 
  
 
(Ly-2), CD19
(ID3), CD4 (RM4-5), CD40 (3/23), CD80 (16-10A1), CD86
(GL-1), CD54 (3E2), CD62L (MEL14), CD24 (M1/69), MHC
II (2G9), CD45 RB (16A), and pan NK (DX5) Abs (all from BD
Biosciences), and anti–PD-L1 (MIH5) and anti–PD-L2 (Ty25;
eBioscience). In experiments where FITC-OVA uptake was
studied, DCs were detected by PE-labeled anti–Gr-1 and APC-
labeled anti-CD11c Abs.
In some experiments, total lung and LN cells were sorted
based on CD11c-APC and Gr-1-FITC staining using a FACS-
DiVa
 
® 
 
flow cytometer (BD Biosciences). Cytospins of the differ-
ent sorted lung cell populations were stained with May-Grun-
wald Giemsa.
 
Confocal Microscopy.
 
Confocal analysis was performed on
6-
 
 
 
m cryostat sections of perfused lungs stained with anti–Gr-1
FITC and anti–B220-PE to detect pDCs. Sections were analyzed
on a confocal laser microscope (LSM-510; Carl Zeiss MicroImag-
ing, Inc.). To detect intracellular uptake of FITC-OVA, cytospins
of CD11c
 
int 
 
Gr-1
 
  
 
cells sorted from MLNs taken 36 h after FITC-
OVA administration were stained with anti–B220-PE, and FITC
signal was observed using confocal laser microscopy.
 
Functional Activity of DC Subsets.
 
To detect the antigen up-
take capacity of DC subsets, mice received an intratracheal (i.t.)
injection of 800 
 
 
 
g FITC-OVA (screened for low LPS content;
Molecular Probes) in a volume of 80 
 
 
 
l PBS. Draining MLNs
were excised 36 h later and analyzed by flow cytometry. To study
antigen-presenting capacity of DC subsets ex vivo, mice first re-
ceived an i.t. injection of 800 
 
 
 
g OVA (LPS content, 
 
 
 
20 pg/
mg OVA; Seikagaku). Next, CD11c
 
int 
 
Gr-1
 
  
 
B220
 
  
 
(pDCs) and
CD11c
 
  
 
Gr-1
 
  
 
B220
 
  
 
cells (mDCs) were sorted from the MLNs
36 h later and cocultured with purified CD4
 
  
 
(purity, 
 
 
 
95% us-
ing magnetic bead purification; Miltenyi Biotec) naive carboxy-
fluorescein diacetate succinimidyl ester (CFSE)-labeled DO11.10
TCR transgenic T cells at a 1:10 ratio. The labeling of T cells
with CFSE was essentially as described previously (10). The stim-
ulatory capacities of lung DC subsets were compared with those
of in vitro OVA-pulsed pDCs or mDCs grown from BM cul-
tures in the presence of Flt3L or GM-CSF, respectively. Genera-
tion of BM DCs was essentially as described previously (23). 4 d
later, proliferation of CD4
 
  
 
KJ1-26
 
  
 
T cells was determined by
flow cytometry.
As IFN-
 
  
 
production by pDCs is a defining characteristic of
these cells, we cultured sorted CD11c
 
int 
 
Gr-1
 
  
 
and CD11c
 
hi
 
Gr-1
 
  
 
DCs in the presence or absence of 2 
 
 
 
M CpG-oligode-
oxynucleotides (5
 
 
 
-TGACTGTG-AACGTTCCGAGATGA-3
 
 
 
;
Sigma-Aldrich). Supernatants were collected 24 h later and ana-
lyzed by ELISA for the presence of IFN-
 
  
 
(PBL Biomedical Lab-
oratory, Inc.).
 
Immune Response to Inhaled OVA in the Presence or Absence of
pDCs.
 
Next, we studied the immune response to harmless in-
haled OVA in mice with or without pDCs. For depletion of
pDCs, 250 
 
 
 
g/ml depleting anti–Gr-1 or control isotype Abs
were given on 4 consecutive days (24), starting 1 d before i.t.
priming with 800 
 
 
 
g LPS
 
low 
 
OVA (LPS contamination of 2.9 ng/
mg protein; Worthington) or, to avoid confounding effects of
LPS, with 800 
 
 
 
g LPS-free OVA (LPS, 
 
 
 
20 pg/mg protein;
Seikagaku). In separate experiments, mice received four i.p. in-
jections of pDC-selective depleting 120G8 Ab (50 
 
 
 
l ascites/
day; provided by C. Asselin-Paturel, Schering-Plough, Dardilly,
France; reference 25). On day 4, the depletion of CD11c
 
int 
 
Gr-1
 
 
 
cells was evaluated on total lung cells and MLNs. Next, we ad-
dressed whether mice were sensitized to inhaled OVA by rechal-
lenging with OVA aerosol. After a wash out period of 20 d, mice
received 3 OVA aerosols (10 mg/ml in PBS, generated using a jet
nebulizer) of 30 min on 3 consecutive days. 24 h later, BAL fluid
was taken and analyzed by flow cytometry as described previously
(26). In brief, eosinophils were characterized as CCR3
 
  
 
SSC
 
hi
 
cells, neutrophils as CCR3
 
  
 
SSC
 
hi 
 
cells, lymphocytes as B220
 
 
 
/
CD3
 
  
 
FSC
 
lo 
 
cells, and macrophages as large autofluorescent cells.
To measure cytokine levels, MLN cells were plated in round-
bottom 96-well plates (10
 
6 
 
cells/ml) and restimulated with 10
 
 
 
g/ml OVA for 4 d. Production of IL-4, IL-5, IL-10, IL-13, and
IFN-
 
  
 
was assayed on supernatants by ELISA (BD Biosciences) as
described previously (12). Levels of OVA-specific IgE were mea-
sured by ELISA as described previously (13). In addition, lungs
were resected and embedded in HistoWax (Intertiles). 4-mm sec-
tions were stained with May-Grunwald Giemsa.
To study primary T cell activation in the lung in the presence
or absence of pDCs, mice received an i.v. injection of 10 
 
  
 
10
 
6
 
CFSE-labeled DO11.10 T cells day 
 
 
 
1 before injection of 0, 8,
80, and 800 
 
 
 
g LPS-free OVA (day 0). From day 
 
 
 
1 to 2, the
mice received an i.p. injection of anti–Gr-1 Abs or control iso-
type Abs (250 
 
 
 
g/day). T cell responses were analyzed in the
draining MLNs at day 4 by observing CFSE division profiles of
live KJ1-26
 
  
 
CD4
 
  
 
T cells. Cytokine levels were measured as de-
scribed above.
 
Induction of Regulatory T (T reg) Cells by Lung pDCs.
 
To de-
tect induction of T reg cells, we used a method recently de-
scribed by Martin et al. (27). First, 800 
 
 
 
g LPS-free OVA was in- 
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jected i.t. and CD11c
 
int 
 
Gr-1
 
  
 
B220
 
  
 
cells were sorted from the
MLNs 36 h later. Sorted DCs were cultured with naive DO11.10
T cells for 3 d at a 1:10 ratio. In the second phase, pDC-stimu-
lated T cells were replated and cultured at 5 
 
  
 
10
 
5 
 
cells per well
in the presence of 1 ng/ml mouse IL-2 (R&D Systems) for an ad-
ditional 7 d without OVA. The T reg cell assay was performed
by culturing freshly purified DO11.10 CD4
 
  
 
T cells (10
 
5 
 
per
well) with irradiated BALB/c splenocytes (10
 
5 
 
per well) in 96-
well plates with 10 
 
 
 
g/ml OVA
 
323-339 
 
peptide in the presence or
absence of pDC-stimulated T cells (10
 
5 
 
per well). Cell prolifera-
tion was assessed after 48 h by [
 
3
 
H]thymidine (1 
 
 
 
Ci/well) up-
take in a 16-h pulse.
 
Adoptive Transfer of pDCs into the Lung.
 
CD11c
 
  
 
CD11b
 
 
 
B220
 
 
 
 
 
pDCs were sorted from Flt3L-cultured BM as described
previously using a FACSDiVa
 
® 
 
flow cytometer (23, 28). 100 
 
 
 
g/
ml OVA was added during the last 24 h of culture. 4 
 
  
 
10
 
5
 
OVA-pulsed or -unpulsed pDCs were injected i.v. three times
on alternate days. 1 wk later, mice received an i.p. injection of
OVA-alum (10 
 
 
 
g OVA adsorbed to 1 mg aluminiumhydroxide;
Sigma-Aldrich; reference 15). Mice were rechallenged three
times with OVA aerosols 10 d later, as described above. 24 h after
the last aerosol exposure, BAL fluid was performed and cell dif-
ferential counts were analyzed by flow cytometry (26).
 
Statistical Analysis.
 
For all experiments, the difference between
groups was calculated using the Mann-Whitney U test for unpaired
data. Differences were considered significant when P 
 
  
 
0.05.
 
Online Supplemental Material.
 
Data showing the phenotype of
DC subsets and IFN-
 
  
 
production by DCs from the lung (Fig.
S1) and the induction of tolerance by a single i.t. injection of
OVA (Fig. S2) are available at: http://www.jem.org/cgi/content/
full/jem.20040035/DC1.
 
Results
 
Different Subtypes of DCs Are Present in the Lung.
 
In hu-
mans and mice, there are two major subsets of DCs, called
mDCs and pDCs. pDCs are known to be present in he-
Figure 1. Identification of pDCs in the lung. (A and B)
After digestion of the lungs, cells were stained for Gr-1 and
CD11c expression, gated on live cells, and analyzed by
flow cytometry. At least six different leukocyte populations
were identified (regions R1–R6). (C) All leukocyte popu-
lations were sorted on Gr-1 and CD11c expression and
stained with May-Grunwald Giemsa. Cytospins showed
typical morphology of lymphocytes (R1), neutrophils
(R2), macrophages (R3), eosinophils (R4), pDCs (R5),
and mDCs (R6). Magnification, 100. (D) Confocal micros-
copy of frozen lung section stained with anti–Gr-1 FITC
(green) and anti–B220-PE (red) Abs. Double positive colo-
calization signal appears orange (blue arrows). (E) Digested
MLNs of naive mice were stained for Gr-1 and CD11c ex-
pression and gated on live cells. CD11cint Gr-1  pDCs and
CD11chi Gr-1  mDCs are shown. (F) MLNs of mice re-
ceiving anti–Gr-1 Abs for 4 d were digested and stained as
described above. Depletion of CD11cint Gr-1  pDCs but
not CD11chi Gr-1  mDCs is shown. 
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matopoietic organs (29, 30), blood (31), and lymphoid or-
gans (32–35), and play a critical role in mounting the pro-
tective immune response to virus infection by producing
large amounts of IFN-
 
  
 
(31, 32, 34). Although lung mDCs
have been described in detail, it is not known if lung also
contains pDCs or what the function of these cells might be.
To analyze the subsets and numbers of DCs present in the
lung of naive mice, whole lungs were digested and stained
for Gr-1 and CD11c, markers known to distinguish be-
tween mDCs (CD11c
 
hi 
 
Gr-1
 
 
 
) and pDCs (CD11c
 
int 
 
Gr-
1
 
 
 
) in the spleen and LNs (35). Several populations of lung
leukocytes could be discriminated by their expression of
Gr-1 and CD11c (Fig. 1, A and B). When sorted, the dif-
ferent populations showed typical morphology of lympho-
cytes, neutrophils, macrophages, eosinophils, pDCs, and
mDCs (Fig. 1 C). At least 50% of the pDCs gated in region
R5 were B220
 
  
 
(27, 35) and expressed CD45RB
 
  
 
(34), yet
none expressed the classical B cell markers or the “lym-
phoid” marker CD8
 
 
 
, expressed on various subsets of
spleen DCs (reference 36; Fig. S1, A and B, available at
http://www.jem.org/cgi/content/full/jem.20040035/DC1).
Furthermore, pDCs had a more immature phenotype than
mDCs as assessed by their lower expression of costimula-
tory molecules and MHC II. On the contrary, the inhibi-
tory B7 family costimulatory molecule PD-L1 was highly
expressed on pDCs compared with mDCs (mean fluores-
cence intensity: 409.5 
 
  
 
42.5 and 328.5 
 
  
 
44.5, respec-
tively; Fig. S1 B).
Confocal microscopy of lung tissues of naive mice con-
firmed that B220
 
  
 
Gr-1
 
  
 
pDCs are a major subset of DCs
that are mainly located in the lung interstitium (Fig. 1 D).
Only CD11c
 
int 
 
Gr-1
 
  
 
cells were able to produce IFN-
 
  
 
in
response to CpG-oligodeoxynucleotides (Fig. S1 C), a de-
fining functional characteristic of pDCs (24, 31). As a posi-
tive control, BM-derived pDCs grown in Flt3L produced
very similar levels of IFN-
 
 
 
, whereas lung mDCs or BM-
derived mDCs did not. As expected, CD11c
 
int 
 
Gr-1
 
  
 
pDCs
were also found in the MLNs of naive mice as described
previously by others (reference 24; Fig. 1 E).
Lung pDCs Prevent Sensitization to Inhaled Harmless Anti-
gen. Next, we questioned if pDCs influence the decision
between tolerance or immunity to inert antigens in the
lung (5). In our protocols using commercially available
OVA screened to contain no or very low levels of LPS en-
dotoxin, a single i.t. injection of OVA did not lead to sen-
sitization or to Th2 cell–associated eosinophilic airway in-
flammation upon repeated challenge with OVA aerosol,
and even lead to suppression of airway inflammation in a
Figure 2. Role of pDCs in asthma.
(A) On day 0, mice received an i.t. in-
jection of LPSlow OVA. From days  1
to 2, mice were injected i.p. with anti–
Gr-1 Abs or isotype control Abs. 20 d
later, mice were exposed to three OVA
aerosols. Lungs of mice depleted or not
of pDCs were stained with periodic
acid-Schiff. (B) Lungs were also stained
with May-Grunwald Giemsa to detect
eosinophils. (C) BAL fluid of mice in-
jected with anti-Gr1 Abs (solid bars) or
with isotype control Abs (shaded bars),
and of naive mice (open bars) was ana-
lyzed by flow cytometry. Data are
shown as mean   SEM. *, P   0.05.
(D) Experiments were repeated using
LPS-free OVA and the depleting Ab
120G8, given at the same time points as
for Gr-1. (E) Sera from mice depleted or
not from pDCs were analyzed for the
presence of OVA-specific IgE. Results
are shown as mean   SEM. *, P   0.05.
(F) MLN cells collected from mice in-
jected with anti-Gr1 Abs (solid bars) or
with isotype control Abs (shaded bars),
and of naive mice (open bars) were
plated and restimulated in vitro for 4 d
with OVA. Supernatants were assayed
for IL-4, IL-5, IL-10, IL-13, and IFN- 
production. Data are shown as mean  
SEM. *, P   0.05.de Heer et al. 93
classical alum-adjuvant–driven animal model of asthma, a
defining characteristic of true immunological tolerance
(Fig. 2 A and Fig. S2, A and B, available at http://
www.jem.org/cgi/content/full/jem.20040035/DC1). To
specifically address the role of pDCs in this process, pDCs
were depleted using anti–Gr-1 Abs. Flow cytometric stain-
ing on draining MLNs (Fig. 1 F) confirmed that this Ab
depleted pDCs but not mDCs as described previously by
others (24). However, in the lung, pDCs were not as
strongly depleted as in the MLNs (unpublished data). pDCs
were depleted during a first exposure to OVA antigen
given by i.t. injection. When challenged with OVA aero-
sols 3 wk later, control mice, as expected (14), did not de-
velop features of asthma (Fig. 2 A). In contrast, pDC-
depleted mice developed cardinal features of asthma as
shown by the eosinophilic inflammation around bronchi
and blood vessels, the occurrence of goblet cell hyperplasia
(Fig. 2, A and B), eosinophilia in the bronchoalveolar com-
partment (Fig. 2 C), and the presence of OVA-specific IgE
in the serum (Fig. 2 E). These characteristics of asthma in
pDC-depleted mice were associated with a substantial in-
crease in Th2 cell cytokine production in MLNs (Fig. 2 F).
These experiments were performed with OVA containing
2.9 ng LPS/mg OVA protein, potentially confounding our
study (14). Moreover, the Gr-1 Ab can also deplete neu-
trophils or other Gr-1  cells. Therefore, the experiments
were also performed with LPS-free OVA using a pDC-
selective depleting Ab 120G8. Under these conditions, ex-
posure to LPS-free OVA also led to sensitization to inhaled
OVA (Fig. 2 D). These observations are strong evidence
that lung pDCs suppress sensitization to otherwise harmless
tolerogenic protein antigens.
Functional Activities of Lung pDCs. Next, we examined
how lung pDCs might influence the immune response to
inhaled antigens. Up to now, it is uncertain whether pDCs
can take up whole antigens (besides viruses) for processing
Figure 3. pDCs transport OVA
from the lung to the draining LNs
but fail to prime naive T cells in
vitro. (A) Mice were injected i.t.
with FITC-OVA. 2 d later, MLNs
were analyzed for the presence of
OVA-loaded pDCs (Gr-1  CD11cint)
and mDCs (Gr-1   CD11chi). (B)
Confocal analysis of FITC-OVA
uptake by pDCs. Mice were injected
i.t. with FITC-OVA. 2 d later,
cytospins of CD11cint Gr-1  FITC-
OVA  cells sorted from MLNs were
prepared and stained with anti-B220
PE Abs. FITC  cells (green, top) are
also positive for B220 (red, bottom)
(C) Mice were injected i.t. with un-
labeled OVA. 2 d later, pDCs (gated
for Gr-1   CD11cint) and mDCs
(gated for Gr-1   CD11chi) were
sorted from MLNs and cocultured
with purified CFSE-labeled CD4  T
cells from DO11.10 mice. 4 d later,
proliferation of OVA-specific T
cells was determined. (D) Cytokine
production by T cells in vitro stimu-
lated with pDCs. OVA-pulsed
pDCs and mDCs were sorted from
MLNs (top) or from the BM (bot-
tom), and cocultured for 4 d with
purified CD4  T cells from DO11.10
mice. Cytokines were assayed in the
supernatants.Plasmacytoid Dendritic Cells Protect against Asthma 94
and presentation. Therefore, FITC-labeled OVA was given
i.t. (11). pDCs as well as mDCs were able to take up
FITC-OVA locally in the lung (unpublished data). Strik-
ingly, after migration to the draining MLNs 36 h later, only
mDCs and pDCs were FITC-OVA . The number of
FITC-OVA  pDCs in the MLNs was higher than FITC-
OVA  mDCs (Fig. 3 A). At this time point,  50% of the
pDCs and mDCs present in the MLNs were positive for
FITC-OVA. Moreover, as shown by confocal microscopy,
FITC-OVA was present inside vacuoles of B220  pDCs
(Fig. 3 B). As both FITC-OVA–loaded pDCs and mDCs
were present in MLNs, their capacity to stimulate naive
TCR-transgenic OVA-specific T cells ex vivo was com-
pared. Only mDCs loaded with OVA in vivo were able to
induce a strong proliferation (78.5% OVA-specific T cells
had divided in response to mDCs vs. only 2.37% with
pDCs; Fig. 3 C). Moreover, OVA-loaded mDCs obtained
from MLNs or derived from the BM induced production
of both Th1 and Th2 cell cytokines by T cells, whereas
pDCs from the lung and BM did not produce cytokine
levels above the level of unstimulated T cells (Fig. 3 D).
pDCs Suppress the Generation of Effector Cells by mDCs In
Vivo. Next, we examined the contribution of pDCs to T
cell division induced by various doses of LPS-free OVA in-
halation by depleting with anti–Gr-1 Abs (37). As the di-
rect examination of naive T cell activation is impossible
due to the low precursor frequency, we adoptively trans-
ferred naive OVA-specific T cells from DO11.10 TCR
transgenic mice. As shown previously (12), without OVA
inhalation, DO11.10 T cells did not divide, whereas after
inhalation of increasing doses of OVA, vigorous prolifera-
tion occurred 4 d later in OVA-specific CD4  T cells of
the MLNs (Fig. 4 A). T cell proliferation was of similar
magnitude in the presence or absence of pDCs regardless of
the dose of OVA used (Fig. 4 A), consistent with the in
vitro observation that pDCs by themselves were unable to
induce T cell proliferation. Although no apparent differ-
ence was detected in terms of T cell proliferation between
mice depleted of pDCs or not, there was a significant in-
crease in the amount of effector cytokines (IL-5, IL-10, IL-
13, and IFN- ) produced by proliferating T cells taken
from immunized pDC-depleted animals (Fig. 4 B, 800- g
dose). This suggests that lung pDCs suppress the generation
of effector function in naive T cells, which proliferate in
response to Ag presentation by mDCs, and provide a
mechanism for the occurrence of sensitization in the ab-
sence of pDCs.
pDCs Induce the Generation of Suppressive T Cells In Vi-
tro. Next, we investigated whether pDCs could be en-
dowed with a tolerogenic potential by inducing T cell un-
responsiveness and the differentiation of T reg cells. T cells
that were first stimulated in vitro with pDCs obtained
Figure 4. pDCs down-regulate the immune response in vivo without affecting T cell division. On day  1, mice were injected i.v. with CFSE-labeled
T cells from DO11.10 mice. On day 0, they received an i.t. injection of different doses of LPS-free OVA (0, 8, 80, and 800  g). (A) From days  1 to 2,
mice were injected i.p. with anti–Gr-1 Abs (gray line) or isotype control Abs (black line), and proliferation of CFSE-labeled OVA-specific T cells was
determined at day 4 in MLNs. (B) MLN cells were plated for 4 d and supernatants were assayed for cytokine production from mice injected with anti-Gr1
Abs (solid bars) or isotype control Abs (shaded bars). Data are mean   SEM. (C) T reg cell assay. Proliferation of OVA-specific T cells after a 2-d coculture
with syngeneic splenocytes and OVA peptide in the presence of T cells previously stimulated with OVA-pulsed pDCs (T cells [OVA-pDCs]) or irrelevant
BALB/c T cells. Cell proliferation was assessed by [3H]thymidine (1  Ci/well) uptake in a 16-h pulse. Data are mean   SEM for triplicate cultures.de Heer et al. 95
from the MLNs of OVA-exposed mice strongly reduced
the proliferation of freshly purified naive T cells from
DO11.10 mice induced by OVA peptide–pulsed spleno-
cyte APCs. This was not due to dilution or to competition
for IL-2, as polyclonal wild-type BALB/c T cells added to
naive DO11.10 T cells and splenocytes in the same propor-
tion did not lead to reduced proliferation (Fig. 4 C). In
conclusion, our data suggest that pDCs induced the differ-
entiation of T reg cells capable of suppressing antigen-spe-
cific T cell proliferation.
Adoptive Transfer of pDCs Prevents Development of Asthma.
Together, these data show that lung pDCs provide an in-
trinsic mechanism to suppress inflammation in response to
inhalation of harmless antigen, and therefore might provide
a mechanism to prevent the occurrence of sensitization. To
more directly demonstrate this intrinsic tolerogenic capac-
ity of pDCs, BM-derived OVA-pulsed pDCs (29) were in-
jected three times i.v. before subjecting mice to a fully im-
munogenic asthma protocol consisting of sensitization by
i.p. injection of OVA in alum, followed by OVA aerosol
challenge (38). As expected, mice receiving no pDCs or
unpulsed pDCs uniformly developed eosinophilic airway
inflammation and goblet cell hyperplasia (Fig. 5, A and B).
In contrast, administration of OVA-pulsed pDCs before
OVA-alum sensitization was able to strongly inhibit the
aerosol-induced BAL eosinophilia (Fig. 5 A), airway in-
flammation (Fig. 5 B), and the production of Th2 cell cy-
tokines by MLN T cells (Fig. 5 C). Although we did not
use lung pDCs because of technical difficulty in obtaining
sufficient cells, these data support the idea that the intrinsic
tolerogenic capacity of pDCs can be exploited to prevent
the onset of asthma.
Discussion
By showing the presence and antigen uptake of pDCs in
the lung, by demonstrating direct priming to antigen in the
absence of pDCs, and by demonstrating transfer of the tol-
erizing effect through injection of pDCs, we believe that
pDCs have an essential immunoregulatory role in the lung
that protects against development of airway inflammation
to harmless antigens.
To our knowledge, this is the first description of pDCs
in the lung of mice. These cells demonstrate intermediate
expression of CD11c, express Gr-1, B220, and CD45RB,
and they produce large amounts of IFN-  after stimulation
with CpG motifs. These cells take up inhaled FITC-OVA
protein and migrate to the MLNs draining the lung carry-
ing their fluorescent cargo inside vacuoles. We believe that
these cells are most likely related to the pDCs also de-
scribed in the draining LNs and spleen of mice (35), and
are distinct from the CD45RB  DCs recently described by
Wakkach et al. (39) by their expression of Gr-1. We are
currently studying if these CD45RB  Gr1  DCs are also
present in the lung.
In the absence of pDCs during primary OVA exposure
to the lung, sensitization was induced, which led to features
of Th2 cell–associated asthma after inhaling harmless anti-
gen. This is a remarkable observation, as primary exposure
to inhaled OVA in our system usually leads to inhalational
tolerance, even when mice are immunized with OVA in
alum (Fig. S2; references 18–21). For our studies in which
we depleted pDCs, we have used Gr-1 Abs that also de-
plete neutrophils (24). We do not believe that absence of
neutrophils had a predominant effect on T cell priming, as
Gr-1  neutrophils did not carry Ag to the node. How-
ever, to more directly prove a role for pDCs as tolerogenic
cells, we used another, more selective pDC-depleting Ab,
120G8, and found identical results, arguing against a pre-
dominant role for the neutrophil (25). Moreover, we per-
formed adoptive transfer experiments before a fully immu-
nogenic asthma protocol. Adoptive transfer of OVA-pulsed
BM-derived pDCs (BM-pDCs) before induction of asthma
completely inhibited airway inflammation. This response
required the presence of OVA, as unpulsed pDCs did not
suppress airway inflammation. Remarkably, under the same
conditions, BM-mDCs did not exert this effect and even
strongly enhanced the cardinal features of asthma (unpub-
lished data and 13).
Next, we performed experiments to elucidate the mech-
anism by which absence of pDCs might lead to sensitiza-
tion. It is known that inhalational tolerance to harmless an-
tigen is accompanied by a significant amount of primary T
cell activation in the draining nodes, and therefore it was
Figure 5. Adoptive transfer of pDCs protects against asthma development. pDCs were sorted from Flt3L-cultured BM, pulsed (solid bars) or not
(shaded bars) with OVA, and injected i.v. three times on alternate days. As a control, some mice were not injected with pDCs (open bars). 1 wk later, all
mice were immunized with OVA-alum i.p. and rechallenged three times with OVA aerosols 10 d later. (A) BAL fluid was analyzed by flow cytometry as
in Fig 2. Data are mean   SEM. *, P   0.05. (B) Lungs from mice injected with OVA-pulsed or -unpulsed pDCs were stained with May-Grunwald
Giemsa. (C) MLN cells were plated for 4 d in the presence of 10  g/ml OVA. Supernatants were assayed for the presence of cytokines. Data are mean  
SEM. *, P   0.05.Plasmacytoid Dendritic Cells Protect against Asthma 96
suggested that depletion of pDCs might influence T cell di-
vision. To our surprise, however, we noticed no difference
in the primary division of naive T cells when the outcome
was either immunity (i.e., in the case of depletion of pDCs)
or tolerance (treatment with control Abs), illustrating that
the strength of primary T cell division does not predict the
functional outcome of a T cell response. Moreover, re-
moving pDCs during OVA inhalation resulted in higher
levels of effector Th2 (IL-5, IL-10, IL-13) and Th1 cell cy-
tokines (IFN- ) being produced by T cells in the draining
MLNs. Indirectly, these data show that the mDC subset is
the predominant APC responsible for inducing naive T cell
proliferation in the draining nodes. The uncoupling of T
cell proliferation from generation of effector potential and
from differentiation into memory cells is emerging as a new
concept in T cell biology (4, 40). Lanzavecchia and Sallusto
(41) recently proposed that T cell stimulation of insufficient
strength or duration leads to proliferation of T cells that are
“unfit” to respond to T cell survival signals and do not pro-
duce effector cytokines. The fact that in our experiments T
cell proliferation was accompanied by proinflammatory ef-
fector T cell generation only when pDCs were depleted,
suggests that pDCs are inefficient APCs that compete with
immunogenic mDCs for antigen presentation, thus effec-
tively reducing the overall strength or duration of T cell
stimulation. From our and previous studies there is evi-
dence that pDCs are weak APCs. Only when pDCs were
pulsed with various doses of OVA peptide in vitro, could
either Th1 or Th2 cell responses be induced (23). The fact
that lung mDCs and pDCs take up fluorescent OVA does
not imply that both cells provide an identical TCR ligand
density, as there might be significant differences in antigen
processing and presentation efficiency (32). Alternatively,
pDCs in the lung and MLNs are immature, expressing low
levels of MHC II and costimulatory molecules, yet high
levels of the inhibitory B7 family member PD-L1 mole-
cule, known to suppress T cell activation through interac-
tion with PD-1 (42). This profile of high inhibitory and
low costimulatory molecule expression together with the
poor T cell stimulatory capacity ex vivo, point out to the
“tolerogenic” potential of pDCs in the lung. It remains to
be demonstrated whether the depletion of pDCs during
priming would also lead to longer survival of responding T
cells as would be predicted from the “T cell fitness” model
(40, 41). Alternative explanations could be that immature
lung pDCs are important for generating T reg cells after
exposure of harmless antigen, as proposed in vitro by others
(27, 29, 39, 43) and also shown indirectly ex vivo here
(Fig. 4 C). In this scenario, in the absence of pDCs, T reg
cells would no longer be induced from naive T cells or ex-
panded from a pool of naturally occurring OVA-responsive
CD4  CD25  regulatory cells (44, 45). The exact pheno-
type and function of these T reg cells induced by lung
pDCs remains to be determined.
Concomitant exposure of harmless antigen with signals
that activate innate immune responses such as viral infec-
tion, bacterial LPS, or GM-CSF, lead to a break in inhala-
tional tolerance presumably through activation of mDCs (4,
7, 14, 46). Supporting this idea, injection of mature mDCs
but not pDCs indeed leads to Th2 cell sensitization in the
lung (unpublished data and 13). We observed induction of
Th2 cell sensitization in response to LPS-free OVA inhala-
tion, which was shown by us (Fig. S2) and by others (47) to
lead to tolerance and did not induce any form of mDC
activation (unpublished data). Therefore, we believe that
modulation of the intrinsic tolerogenic function of pDCs
represents a second mechanism by which “adjuvant factors”
lead to Th2 cell sensitization to harmless antigens. In this
context, there is a known association between respiratory
viral infections such as respiratory syncytial virus at a young
age and the development of asthma (48). As viruses strongly
interact with pDCs, we propose that inhibition of the nor-
mal tolerogenic activities of lung pDCs by viral infection
could be the mechanism behind this association. Viral in-
fections induce maturation of pDCs in vivo and this might
explain the breaking of inhalational tolerance (37). Some
“adjuvants” might also alter the ratio between immuno-
genic mDCs and pDCs in the lung and thus influence the
decision between immunity and tolerance. This was nicely
shown in the case of adenoviral transfection of the lung
with GM-CSF, a predominant growth factor for mDCs but
not pDCs, which led to sensitization (46). It will be inter-
esting to study if increasing pDCs would have the opposite
effect. It is striking that administration of CpG motifs to the
lung leads to strong accumulation of lung pDCs (unpub-
lished data) and to protection from asthma through unclear
mechanisms not mediated by Th1 cell cytokines (49).
The discovery that pDCs influence the generation of T
cell effector responses has extensive implications for our
understanding of immunoregulation in a wide range of T
cell–mediated diseases. Inhibition of the tolerogenic capac-
ity of pDCs could thus offer an explanation why some viral
infections lead to a break in peripheral self-tolerance in a
number of autoimmune diseases such as diabetes (50, 51).
In light of our findings, it will be very interesting to see
whether the function of lung pDCs in humans with allergy
or asthma would also be reduced, thus favoring Th2 cell
sensitization to inhaled antigen (52). One recent report
showed that the number of circulating pDCs in children
with atopic asthma was reduced compared with healthy
controls (53).
In conclusion, we have identified a role for endogenous
pDCs in the protection against asthmatic reactions to
harmless antigens by demonstrating that asthma develops in
the absence of pDCs. Therefore, aberrant function of
pDCs might contribute to allergic sensitization. Therapies
targeted at amplifying the intrinsic tolerogenic capacity of
lung pDCs may limit the development of asthma.
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